A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)

The Beacon
22/01/2018 6 min
A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)

Listen "A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.

More episodes of the podcast The Beacon

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075) 08/03/2019
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074) 05/03/2019
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073) 28/12/2018
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072) 21/12/2018
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071) 11/12/2018
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070) 09/12/2018
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069) 04/12/2018
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068) 02/12/2018
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067) 16/11/2018
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066) 14/11/2018
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA